Literature DB >> 10928690

Multi-center retrospective evaluation of oral benzocaine exposure in children.

H A Spiller1, D H Revolinski, M L Winter, J A Weber, S E Gorman.   

Abstract

On rare occasions benzocaine has produced methemoglobinemia from oral, rectal and dermal exposures. There is disagreement whether this is an idiosyncratic event or a dose-related event. To gain a better perspective on this problem we retrospectively reviewed cases at 4 large regional poison centers of children <18-y of age from 1993-1996. One hundred and eighty-eight benzocaine exposures were reported. Mean and median ingested dosage were 86.8 (+/- 89.5) mg/kg and 50 mg/kg, respectively. Fifty-eight patients (30%) were managed in the emergency department; 8 patients had methemoglobin levels determined. One child had a methemoglobin level of 19%; all others were <1%. One hundred and seventy-three patients (92%) remained asymptomatic. Other symptoms were minor: oral numbness (8), vomiting (3), and 1 each of oral irritation, dizziness and nausea. In this series of accidental ingestions of benzocaine-containing products cyanosis was rare and apparently not dose related. These cases may be safely managed at home with telephone follow up for at least 2 h. If there is evidence of cyanosis, dusky pallor, shortness of breath, or change in mental status direct medical evaluation should be recommended.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10928690

Source DB:  PubMed          Journal:  Vet Hum Toxicol        ISSN: 0145-6296


  3 in total

1.  Pediatric Exposures to Topical Benzocaine Preparations Reported to a Statewide Poison Control System.

Authors:  Rais Vohra; Serena Huntington; Jennifer Koike; Kevin Le; Richard J Geller
Journal:  West J Emerg Med       Date:  2017-07-14

2.  Code Blue: Life-threatening Methemoglobinemia.

Authors:  José D Ponce Ríos; Rothsovann Yong; Paul Calner
Journal:  Clin Pract Cases Emerg Med       Date:  2019-03-27

3.  Toxic methemoglobinemia treated with ascorbic Acid: case report.

Authors:  Hatice Topal; Yasar Topal
Journal:  Iran Red Crescent Med J       Date:  2013-12-05       Impact factor: 0.611

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.